The Cheapest Way to Get Semaglutide Legally: Every Option Compared

Two years ago this article would have been short and depressing. In 2026 there are genuinely eight legal routes to semaglutide in the United States, and the spread between the cheapest and the most expensive is more than fiftyfold.

Below is every option, what it actually costs, who qualifies, and the catch attached to each. The word “legally” is doing real work here: there are cheaper things advertised online that are not legal, not FDA approved, or both, and those get their own section.

This is a cost guide, not medical advice. Which semaglutide product is right for you, and whether one is appropriate at all, is a decision for you and a healthcare provider.

The quick comparison

Route	Monthly cost	Who qualifies
Commercial insurance + savings card	as little as $25	Commercial plan that covers the drug
Medicare GLP-1 Bridge	$50	Medicare Part D, obesity criteria, through 2027
Patient Assistance Program	$0	Uninsured, income ≤200% FPL, Ozempic only
Wegovy or Ozempic pill (self-pay)	$149-$299	Anyone paying cash
Wegovy pen, 12-month subscription	$249	Self-pay, via telehealth partners
Wegovy or Ozempic pen, introductory	$199 (2 fills)	New self-pay patients, through 12/31/2026
Wegovy or Ozempic pen, standard	$349	Anyone paying cash
Wegovy HD 7.2 mg / Ozempic 2 mg	$399 / $499	Anyone paying cash
No program, list price	$1,027-$1,349	Nobody should end up here

1. Insurance plus the savings card: as little as $25

If your commercial plan covers the drug, this is almost always the cheapest route and nothing else comes close.

Novo Nordisk’s savings offers for both Wegovy and Ozempic let eligible patients pay as little as $25 a month, with a maximum savings of $100 per one-month prescription (verified 2026-09-14) [1][2]. That $25 is a savings-card price for people with commercial coverage, not a cash price. Enrollment is free; for Wegovy you can text SAVE to 83757 or use the online form.

The catch is the $100 cap. If your plan copay is $125 or less, you land at $25. If your plan uses coinsurance against a $1,349 list price, the card knocks $100 off a much bigger number.

You must be 18 or older with commercial or private drug insurance that covers the medication. Medicare, Medicaid, TRICARE and VA enrollees are excluded from the $25 copay reduction. Novo Nordisk does let government-insured patients use the same enrollment to reach the self-pay prices below, but only if they pay outside their insurance and do not seek reimbursement.

2. Medicare GLP-1 Bridge: $50

Since July 1, 2026, Medicare Part D enrollees who meet the clinical criteria can get Wegovy injection or tablets, Foundayo tablets, or the Zepbound KwikPen for a flat $50 copay through a temporary CMS demonstration [3].

Eligibility: 18 or older with Medicare drug coverage and a BMI of 35+; or 30+ with diastolic heart failure, uncontrolled hypertension or stage 3a+ chronic kidney disease; or 27+ with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. You are not eligible if your Part D plan already covers your GLP-1, or if you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease [3].

The catches: the program is scheduled to end December 31, 2027, the $50 does not count toward your Part D deductible or out-of-pocket cap, and Extra Help does not reduce it.

3. Patient Assistance Program: free, if you qualify

Novo Nordisk’s PAP provides free medicine with no registration or monthly fees. As of 2026, uninsured applicants need total household income at or below 200% of the federal poverty level for Ozempic, and Medicare Part D beneficiaries are no longer eligible [4].

Two limits: it is a diabetes program, so it does not cover Wegovy for weight loss, and the income threshold is genuinely low.

4. The pill at $149 to $299: the cheapest cash route

This is the option most people do not know about.

Oral semaglutide is sold as the Wegovy pill (25 mg, approved for chronic weight management in December 2025) and the Ozempic pill (approved for type 2 diabetes; this product was called Rybelsus until Novo Nordisk renamed it in 2026). Self-pay prices for both [5][6]:

• 1.5 mg: $149/month
• 4 mg: $199/month
• 9 mg: $299/month
• 25 mg (Wegovy only): $299/month

One month is one bottle of 30 tablets.

The catch is not financial. Oral semaglutide has strict administration rules: it must be taken first thing in the morning on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before any food, drink or other oral medication. Whether that fits your life, and whether the pill is clinically appropriate for you, is a conversation with your prescriber.

5. The 12-month subscription at $249

Since March 31, 2026, self-pay patients can enroll in a multi-month Wegovy subscription through participating telehealth platforms. Novo Nordisk launched it with Ro, WeightWatchers and LifeMD, and named Hims & Hers, Sesame and others as coming online after that [7][8]:

• 3 months: $329/month
• 6 months: $299/month
• 12 months: $249/month

The 9 mg and 25 mg pills follow the same structure at $289, $269 and $249.

Two catches. You are committing to a term. And telehealth platforms usually charge their own membership or program fee on top of the medication price, so ask what the all-in number is before enrolling. A $249 drug price with a $99 monthly membership is not a $249 option.

6. The $199 introductory offer, then $349

For anyone new to the Novo Nordisk savings offer or NovoCare Pharmacy, the two lowest doses of either Wegovy (0.25 mg, 0.5 mg) or Ozempic (0.25 mg, 0.5 mg) are $199 a month for the first two fills, an offer running through December 31, 2026 [9].

After that, the standard self-pay price is:

• Wegovy pen: $349/month for 0.25 mg through 2.4 mg; $399/month for Wegovy HD 7.2 mg
• Ozempic pen: $349/month for 0.25 mg, 0.5 mg and 1 mg; $499/month for 2 mg

These prices are reachable four different ways at the same price [5][10][11]:

• NovoCare Pharmacy: your prescriber sends the prescription; free home delivery, or retail pharmacy pickup (NovoCare’s own page describes pickup without naming a chain or a location count)
• Retail pharmacies: register at wegovy.com or ozempic.com and use the offer at 70,000+ locations
• GoodRx: carries the same prices
• TrumpRx.gov: issues a coupon you present at a participating pharmacy [11]

Pick on convenience, not price. They are the same offer delivered four ways.

7. Non-semaglutide GLP-1s that compete on price

Worth knowing about, though these are different molecules and the choice is clinical rather than purely financial.

Foundayo (orforglipron), Eli Lilly’s once-daily pill approved April 1, 2026, is priced by dose. Lilly’s published regular self-pay prices are $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg. Through December 31, 2026 the 2.5 mg dose is temporarily cut to $149 and the 5.5 mg dose to $199, and the two highest doses carry a $299 purchase offer if you refill within 45 days of your last delivery. With commercial coverage the savings card can bring it to $25 a month, capped at $100 per one-month fill and $1,000 a year [12]. Unlike oral semaglutide, it has no food or water timing restrictions.

Zepbound (tirzepatide) runs $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg through LillyDirect’s Self Pay Journey Program, provided you refill within 45 days [13]. Miss the window and the regular prices apply: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg.

8. List price: the route to avoid

If you have no coverage and use no program, you are billed against $1,027.51 for Ozempic or $1,349.02 for Wegovy [11]. Nobody should end up here, but people do, usually because the pharmacy ran the claim through a plan that does not cover the drug and nobody offered the self-pay option.

If your pharmacy quotes you four figures, stop and ask them to run the manufacturer self-pay offer instead.

One structural note: Novo Nordisk has announced it will cut the list price of Wegovy, Ozempic and Rybelsus to $675 a month effective January 1, 2027. That matters most for people with coinsurance or an unmet deductible, whose bill is calculated from list price.

What about compounded semaglutide?

This is where the “cheapest” question gets complicated, and where a lot of online advice is either outdated or selling something.

Telehealth platforms still advertise compounded semaglutide at roughly $99 to $499 a month, with the lowest numbers tied to long prepaid terms. Those are advertised rates, not verified transaction data.

The legal picture has narrowed sharply:

• The FDA declared the semaglutide injection shortage resolved on February 21, 2025, which removed the legal basis most compounders relied on [14]
• Compounders sued and lost their preliminary injunction motions; the enforcement deadlines held
• On April 1, 2026, the FDA restated that semaglutide appears on neither the 503B bulks list nor the shortage list, effectively closing outsourcing facilities [14]
• Under 503A, the FDA said it does not intend to act against a compounder filling four or fewer prescriptions of an essentially-a-copy product per calendar month
• The FDA specifically warned that adding vitamin B12 to semaglutide does not by itself avoid the essentially-a-copy finding when strengths are within 10% of the commercial products [14]
• On April 30, 2026 the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list

Compounded semaglutide is not FDA approved. It is not reviewed for safety, effectiveness or manufacturing quality, and it is not a generic. Meanwhile the branded price gap that made compounding attractive has largely closed: a $149 Wegovy pill or a $249 subscription pen is competitive with most advertised compounded pricing, and it is an FDA-approved product from a regulated supply chain.

Three rules that will save you money

Check your copay before you reach for a coupon. If your plan covers the drug and the savings card gets you to $25, that beats every cash price on the market. People routinely pay $349 cash when $25 was available.

Remember that cash does not count. Novo Nordisk, Eli Lilly and TrumpRx all require you to agree that self-pay purchases will not be submitted for reimbursement and will not count toward your deductible or out-of-pocket limit [11][1]. If you are close to meeting a deductible, running the drug through insurance may be worth more than the discount.

Read the expiration dates. The $199 introductory offer runs through December 31, 2026. The temporary $149 price on the 4 mg Wegovy pill ended August 31, 2026. Every one of these programs says the manufacturer can modify or cancel it at any time. Verify the current price before you budget around it.

Sources

1. Savings Offer Program for Wegovy — NovoCare, retrieved 2026-09-14
2. Ozempic pill and pen price guide — Novo Nordisk, 2026-05
3. Weight loss drugs — Medicare.gov, retrieved 2026-09-14
4. Novo Nordisk Patient Assistance Program (PAP) — NovoCare, 2026-08-05
5. Wegovy price guide — Novo Nordisk, retrieved 2026-09-14
6. NovoCare Pharmacy — Novo Nordisk, retrieved 2026-09-14
7. Novo Nordisk launches multi-month subscription program for Wegovy — Novo Nordisk, 2026-03-31
8. Novo Nordisk to launch discounted Wegovy subscriptions — Reuters, 2026-03-31
9. Novo Nordisk launches introductory self-pay offer for $199 per month — Novo Nordisk, 2025-11-17
10. GoodRx Launches $39 Per Month Weight Loss Telemedicine Subscription — GoodRx, 2025-11-17
11. Ozempic Pen on TrumpRx — TrumpRx.gov, retrieved 2026-09-14
12. Foundayo Coverage and Savings — Eli Lilly, retrieved 2026-09-14
13. Lilly lowers the price of Zepbound single-dose vials — Eli Lilly, 2025-12
14. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA, 2026-04-01
15. TrumpRx — US Government, retrieved 2026-09-14